RECRUITINGOBSERVATIONAL
Intracranial PrEssure Time dOse (ImPETO)
Evaluation of Intracranial Pressure Time Dose by the New Integra CereLink ICP Monitor
About This Trial
The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting. Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.
Who May Be Eligible (Plain English)
Who May Qualify:
- Aged within 18 and 80 years;
- Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;
- ICP monitoring started for clinical indication and accordingly to local policies
- ICP device connected to the Integra CereLink ICP monitor.
Who Should NOT Join This Trial:
- ICP monitoring not inserted
- No availability of the Integra CereLink ICP monitor.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Aged within 18 and 80 years;
* Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;
* ICP monitoring started for clinical indication and accordingly to local policies
* ICP device connected to the Integra CereLink ICP monitor.
Exclusion Criteria:
* ICP monitoring not inserted
* No availability of the Integra CereLink ICP monitor.
Treatments Being Tested
PROCEDURE
intracranial pressure monitoring
Invasive monitoring of intracranial pressure by using CereLink monitor.
Locations (1)
Fondazione IRCCS San Gerardo dei Tintori
Monza, MB, Italy